Monitoring Neonatal Hypoglycemia with the Accu-chek Advantage II Glucose Meter: The Cautionary Tale of Galactosemia
The DOI matches its Crossref record.
Abstract
Hand-held glucose meters are a practical solution for measuring glucose in neonatal intensive care units and special care nurseries because of their portability, the immediacy of results, and minimal blood volume requirements compared with dispatching samples for central laboratory analysis. We have used the Roche Accu-chek Advantage II meter for some time in our neonatal intensive care unit, but we no longer use it in view of the following findings. Nonidentical twins, born 4 weeks prematurely, were managed in our special care nursery. Twin 2 was found to have increasing glucose over the first 24 h, reaching a maximum of 16.8 mmol/L as measured at the point of care (POC) with the Accu-chek Advantage II meter. When a sample was sent to the laboratory for confirmation of this increased glucose, the laboratory result (measured with the hexokinase assay on a Dade-Behring Dimension RxL analyzer) was only 1.0 mmol/L. Additional investigations (including galactitol measurements) later confirmed that the baby suffered from galactosemia. Subsequently, we compared the effects of galactose addition to whole-blood samples on results of the Accu-chek Advantage II, three other commonly used devices for POC measurement of blood glucose, and a hexokinase method on a Dade-Behring Dimension RxL analyzer (Fig. 1). Galactose (2.5–20 mmol/L) produced an equimolar overestimation of glucose by the Accu-chek Advantage II, indicating no discrimination between glucose and galactose by this device, whereas the other methods were unaffected. Comparison of blood glucose measurement methods. Galactose was added to heparinized whole blood and measured with the Advantage II, Precision Q.I.D., Optium, and AVL OMNI 9 and compared with plasma glucose measurement by the hexokinase reference method for glucose with a Dade-Behring Dimension RxL analyzer. HK, hexokinase; GOX, glucose oxidase; GDH, glucose dehydrogenase. Glucose methods that use hexokinase and POC devices that use glucose oxidase (e.g., the AVL OMNI 9 analyzer and the Medisense Precision Q.I.D.TM) were not affected by galactose. Although it would appear that the discrepancy found with the Accu-chek Advantage II could be caused by the use of glucose dehydrogenase (GDH) to measure glucose by this device, we found that two other POC glucose measurement systems that also use GDH, the MediSense Optium glucose analyzer (Fig. 1) and the HemoCue B-Glucose analyzer (Joakim Hagvik, HemoCue, personal communication) were not affected by galactose. Thus it appears that it may be the source of the GDH or its formulation that leads to the measurement of galactose as glucose. The product information sheet with Accu-chek Advantage II glucose reagent strips indicates that “Galactose >10 mg/dL (0.56 mmol/L) may give falsely increased results”. We suggest that specific reference should be made to the equimolar interference of galactose with glucose and the possibility of gross overestimation of glucose in the case of galactosemia. We also recommend that all unexpectedly high POC results must be confirmed by laboratory measurement before initiation of treatment. We are grateful to Surjit Bedi of MediSense for providing an Optium glucose analyzer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ceriotti, F., Kaczmarek, E., Guerra, E., Mastrantonio, F., Lucarelli, F., Valgimigli, F., & Mosca, A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814563351 · Cited by 45
“The consequences of inaccurate readings in terms of managing neonates with galactosemia have previously been reported.(34,35) This study focused primarily on assessing the current versions of combined glucose/BHB meter combinations with interferences reported to be associated with glucose meter adverse events.”
BackgroundPerera, N. J., Stewart, P. M., Williams, P. F., Chua, E. L., Yue, D. K., & Twigg, S. M. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03362.x · Cited by 33
Warner, J. V., Wu, J. Y., Buckingham, N., McLeod, D. S. A., Mottram, B., & Carter, A. C. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0129 · Cited by 20
Tendl, K. A., Christoph, J., Bohn, A., Herkner, K. R., Pollak, A., & Prusa, A.-R. (2013) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2012-0864 · Cited by 18
Metadata
- Authors
- Newman, J. D., Ramsden, C. A., & Balazs, N. D.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 48
- Issue
- 11
- Pages
- 2071-2071
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2108999139
- Cited by
- 29
- References
- 0
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring Neonatal Hypoglycemia with the Accu-chek Advantage II Glucose Meter: The Cautionary Tale of Galactosemia. https://app.cochat.ai/papers/10.1093/clinchem/48.11.2071
- The paper
- Newman, J. D., Ramsden, C. A., & Balazs, N. D. (2002). Monitoring Neonatal Hypoglycemia with the Accu-chek Advantage II Glucose Meter: The Cautionary Tale of Galactosemia. Clinical Chemistry. https://doi.org/10.1093/clinchem/48.11.2071
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.